
Denali sells Rare Pediatric Disease Priority Review Voucher for $195M to fund neurodegenerative drug development.
Denali Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million. The PRV was awarded after FDA approval of AVLAYAH™, the first biologic designed to cross the blood-brain barrier for treating Hunter syn...


